Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Notes Payables: 2021-2024

Historic Notes Payables for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $4,896.

  • ProQR Therapeutics N.V's Notes Payables rose 13.29% to $5,611 in Q3 2025 from the same period last year, while for Sep 2025 it was $5,611, marking a year-over-year increase of 13.29%. This contributed to the annual value of $4,896 for FY2024, which is 5.46% up from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported Notes Payables of $4,896 as of FY2024, which was up 5.46% from $4,643 recorded in FY2023.
  • Over the past 5 years, ProQR Therapeutics N.V's Notes Payables peaked at $5.6 million during FY2021, and registered a low of $4,643 during FY2023.
  • Its 3-year average for Notes Payables is $1.5 million, with a median of $4,896 in 2024.
  • Its Notes Payables has fluctuated over the past 5 years, first plummeted by 99.89% in 2023, then increased by 5.46% in 2024.
  • Over the past 4 years, ProQR Therapeutics N.V's Notes Payables (Yearly) stood at $5.6 million in 2021, then fell by 22.82% to $4.4 million in 2022, then slumped by 99.89% to $4,643 in 2023, then rose by 5.46% to $4,896 in 2024.